Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
YCBD vs ACB
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
YCBD vs ACB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $9M | $201M |
| Revenue (TTM) | $19M | $361M |
| Net Income (TTM) | $-328M | $41M |
| Gross Margin | 59.8% | 62.7% |
| Operating Margin | -5.7% | 13.3% |
| Forward P/E | — | 168.8x |
| Total Debt | $778M | $104M |
| Cash & Equiv. | $2M | $184M |
YCBD vs ACB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| cbdMD, Inc. (YCBD) | 100 | 0.2 | -99.8% |
| Aurora Cannabis Inc. (ACB) | 100 | 2.5 | -97.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: YCBD vs ACB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
YCBD is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.66
- Lower volatility, beta 0.66, current ratio 2.05x
- Beta 0.66, current ratio 2.05x
ACB carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- -92.2% 10Y total return vs YCBD's -100.0%
- 27.0% revenue growth vs YCBD's -1.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.0% revenue growth vs YCBD's -1.5% | |
| Quality / Margins | 11.2% margin vs YCBD's -6.5% | |
| Stability / Safety | Beta 0.66 vs ACB's 1.81 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -10.5% vs ACB's -23.2% | |
| Efficiency (ROA) | 5.2% ROA vs YCBD's -27.8%, ROIC 0.7% vs -0.4% |
YCBD vs ACB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ACB leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACB is the larger business by revenue, generating $361M annually — 19.2x YCBD's $19M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to YCBD's -6.5%. On growth, YCBD holds the edge at +980.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $19M | $361M |
| EBITDAEarnings before interest/tax | -$286M | $71M |
| Net IncomeAfter-tax profit | -$328M | $41M |
| Free Cash FlowCash after capex | -$853M | -$31M |
| Gross MarginGross profit ÷ Revenue | +59.8% | +62.7% |
| Operating MarginEBIT ÷ Revenue | -5.7% | +13.3% |
| Net MarginNet income ÷ Revenue | -6.5% | +11.2% |
| FCF MarginFCF ÷ Revenue | -16.9% | -8.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +980.1% | +6.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.6% | -94.5% |
Valuation Metrics
YCBD leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $9M | $201M |
| Enterprise ValueMkt cap + debt − cash | $785M | $142M |
| Trailing P/EPrice ÷ TTM EPS | -0.84x | 168.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.00x |
| Price / SalesMarket cap ÷ Revenue | 0.48x | 0.79x |
| Price / BookPrice ÷ Book value/share | 0.51x | 0.44x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ACB leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-4 for YCBD. ACB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to YCBD's 107.70x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs YCBD's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -3.6% | +7.2% |
| ROA (TTM)Return on assets | -27.8% | +5.2% |
| ROICReturn on invested capital | -0.4% | +0.7% |
| ROCEReturn on capital employed | -47.1% | +0.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 107.70x | 0.17x |
| Net DebtTotal debt minus cash | $776M | -$80M |
| Cash & Equiv.Liquid assets | $2M | $184M |
| Total DebtShort + long-term debt | $778M | $104M |
| Interest CoverageEBIT ÷ Interest expense | — | 6.27x |
Total Returns (Dividends Reinvested)
ACB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACB five years ago would be worth $418 today (with dividends reinvested), compared to $7 for YCBD. Over the past 12 months, YCBD leads with a -10.5% total return vs ACB's -23.2%. The 3-year compound annual growth rate (CAGR) favors ACB at -18.3% vs YCBD's -61.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -21.3% | -18.4% |
| 1-Year ReturnPast 12 months | -10.5% | -23.2% |
| 3-Year ReturnCumulative with dividends | -94.4% | -45.5% |
| 5-Year ReturnCumulative with dividends | -99.9% | -95.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -92.2% |
| CAGR (3Y)Annualised 3-year return | -61.8% | -18.3% |
Risk & Volatility
Evenly matched — YCBD and ACB each lead in 1 of 2 comparable metrics.
Risk & Volatility
YCBD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than ACB's 1.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACB currently trades 53.1% from its 52-week high vs YCBD's 35.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 1.81x |
| 52-Week HighHighest price in past year | $2.56 | $6.67 |
| 52-Week LowLowest price in past year | $0.47 | $3.07 |
| % of 52W HighCurrent price vs 52-week peak | +35.6% | +53.1% |
| RSI (14)Momentum oscillator 0–100 | 51.9 | 48.7 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 975K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $5.92 |
| # AnalystsCovering analysts | — | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
ACB leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). YCBD leads in 1 (Valuation Metrics). 1 tied.
YCBD vs ACB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is YCBD or ACB a better buy right now?
For growth investors, Aurora Cannabis Inc.
(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus -1. 5% for cbdMD, Inc. (YCBD). Aurora Cannabis Inc. (ACB) offers the better valuation at 168. 8x trailing P/E, making it the more compelling value choice. Analysts rate Aurora Cannabis Inc. (ACB) a "Hold" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YCBD or ACB?
Over the past 5 years, Aurora Cannabis Inc.
(ACB) delivered a total return of -95. 8%, compared to -99. 9% for cbdMD, Inc. (YCBD). Over 10 years, the gap is even starker: ACB returned -92. 2% versus YCBD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YCBD or ACB?
By beta (market sensitivity over 5 years), cbdMD, Inc.
(YCBD) is the lower-risk stock at 0. 66β versus Aurora Cannabis Inc. 's 1. 81β — meaning ACB is approximately 173% more volatile than YCBD relative to the S&P 500. On balance sheet safety, Aurora Cannabis Inc. (ACB) carries a lower debt/equity ratio of 17% versus 108% for cbdMD, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — YCBD or ACB?
By revenue growth (latest reported year), Aurora Cannabis Inc.
(ACB) is pulling ahead at 27. 0% versus -1. 5% for cbdMD, Inc. (YCBD). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to 39. 1% for cbdMD, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — YCBD or ACB?
Aurora Cannabis Inc.
(ACB) is the more profitable company, earning 0. 5% net margin versus -10. 6% for cbdMD, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -11. 3% for YCBD. At the gross margin level — before operating expenses — YCBD leads at 56. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — YCBD or ACB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is YCBD or ACB better for a retirement portfolio?
For long-horizon retirement investors, cbdMD, Inc.
(YCBD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Aurora Cannabis Inc. (ACB) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YCBD: -100. 0%, ACB: -92. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between YCBD and ACB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: YCBD is a small-cap quality compounder stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.